NEW—UK’s #COVID19 vaccine is safe and induces an immune reaction, according to preliminary results hubs.ly/H0sK2Km0
Preliminary results from a phase 1/2 trial involving 1077 healthy adults found that vaccine induced strong antibody & T cell immune responses up to day 56 of the ongoing trial. These responses may be even greater after a 2nd dose, according to a sub-group study of 10 participants
Compared to control group (given a meningitis vaccine), SARS-CoV-2 vaccine caused minor side effects more frequently, but some of these could be reduced by taking paracetamol. There were no serious adverse events from the vaccine
Fatigue & headache were the most commonly reported reactions (70% [340/487] of all participants given #COVID19 vaccine only reported fatigue & 68% [331/487] reported headache, vs 48% [227/477] & 41% [195/477], respectively, of participants in control group without paracetamol)
T cell responses targeting SARS-CoV-2 spike protein were markedly increased (in the 43 participants studied), peaking after 14 days. The T cell response did not increase with a 2nd dose of the vaccine, which is consistent with other vaccines of this kind
Antibody responses peaked by day 28 (median 157 ELISA units–studied in 127 participants) & remained high until d 56 (median 119 ELISA units–in 43 participants) for those given 1 dose. This response was boosted by a 2nd dose(median 639 ELISA units at d 56 in these 10 participants)
These antibody responses were present in all participants who had a booster dose of the vaccine (9 of 9 participants in MNA80 assay at day 42, and 10 of 10 in Marburg VN assay on day 56)
Authors say further clinical studies, including in older adults, should be done with this vaccine. Current results focus on immune response measured in the laboratory. Further testing is needed to confirm if vaccine effectively protects against infection hubs.ly/H0sK2Km0

Create an account for weekly updates and features such as bookmarks & reading history.